{"id":421,"date":"2026-06-05T23:25:42","date_gmt":"2026-06-05T23:25:42","guid":{"rendered":"https:\/\/bangkokpeptidecenter.com\/?p=421"},"modified":"2026-06-05T23:25:43","modified_gmt":"2026-06-05T23:25:43","slug":"retatrutide-vs-tirzepatide","status":"publish","type":"post","link":"https:\/\/bangkokpeptidecenter.com\/th\/retatrutide-vs-tirzepatide\/","title":{"rendered":"Retatrutide vs. Tirzepatide"},"content":{"rendered":"<div class=\"bpc-blog\" style=\"font-family:'DM Sans',sans-serif;color:#1A1520;max-width:720px;margin:0 auto;line-height:1.8;\">\n\n<style>\n.bpc-blog h2{font-family:'Fraunces',serif;font-weight:400;font-size:1.5rem;color:#1A1520;margin:2.5rem 0 0.8rem;letter-spacing:-0.01em;}\n.bpc-blog h3{font-family:'DM Sans',sans-serif;font-weight:600;font-size:1.05rem;color:#1A1520;margin:2rem 0 0.6rem;}\n.bpc-blog p{font-size:15px;color:#4A4258;margin-bottom:1.2rem;}\n.bpc-blog a{color:#7B2FBE;text-decoration:none;border-bottom:1px solid rgba(123,47,190,0.2);transition:border-color 0.2s;}\n.bpc-blog a:hover{border-color:#7B2FBE;}\n.bpc-blog .blog-intro{font-size:17px;color:#1A1520;font-weight:300;line-height:1.9;margin-bottom:2rem;border-left:3px solid #7B2FBE;padding-left:1.2rem;}\n.bpc-blog table{width:100%;border-collapse:collapse;margin:1.5rem 0 2rem;font-size:14px;}\n.bpc-blog thead th{text-align:left;padding:0.8rem 1rem;background:#F3EDFC;color:#4A4258;font-weight:600;font-size:12px;text-transform:uppercase;letter-spacing:0.06em;border-bottom:2px solid #E8E2F0;}\n.bpc-blog thead th:first-child{border-radius:8px 0 0 0;}\n.bpc-blog thead th:last-child{border-radius:0 8px 0 0;}\n.bpc-blog tbody td{padding:0.7rem 1rem;border-bottom:1px solid #F3F0F7;color:#4A4258;}\n.bpc-blog tbody tr:last-child td{border-bottom:none;}\n.bpc-blog .blog-cta{background:linear-gradient(135deg,#1A1520,#2D1B4E);border-radius:14px;padding:2rem;text-align:center;margin:2.5rem 0;}\n.bpc-blog .blog-cta h2{color:#fff;font-size:1.4rem;margin:0 0 0.5rem;}\n.bpc-blog .blog-cta p{color:rgba(255,255,255,0.7);font-size:14px;margin-bottom:1.2rem;}\n.bpc-blog .blog-cta a{display:inline-block;background:#7B2FBE;color:#fff;padding:12px 28px;border-radius:10px;font-size:14px;font-weight:500;border:none;text-decoration:none;margin:0 6px;}\n.bpc-blog .blog-cta a:hover{background:#6B24A8;}\n.bpc-blog .blog-cta a.secondary{background:transparent;border:1px solid rgba(255,255,255,0.3);color:rgba(255,255,255,0.8);}\n.bpc-blog .blog-cta a.secondary:hover{border-color:#fff;color:#fff;}\n.bpc-blog .blog-disclaimer{font-size:12px;color:#8B7FA0;margin-top:2rem;padding-top:1.5rem;border-top:1px solid #E8E2F0;line-height:1.7;}\n.bpc-blog .source-list{font-size:12.5px;color:#8B7FA0;margin-top:2rem;padding:1.2rem 1.5rem;background:#F9F7FC;border-radius:10px;border:1px solid #E8E2F0;}\n.bpc-blog .source-list strong{color:#4A4258;display:block;margin-bottom:0.5rem;font-size:11px;text-transform:uppercase;letter-spacing:0.1em;}\n.bpc-blog .source-list a{color:#7B2FBE;font-size:12.5px;}\n<\/style>\n\n<p class=\"blog-intro\">Retatrutide and Tirzepatide are the two most researched GLP-1 receptor agonists in metabolic peptide science right now. Both target incretin pathways. Both have produced significant clinical results. But they work through different mechanisms, and the data behind each tells a distinct story. Here\u2019s how they compare.<\/p>\n\n<h2>What they are<\/h2>\n\n<p><a href=\"\/th\/product\/buy-tirzepatide-bangkok\/\">Tirzepatide<\/a> is a dual agonist that activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Available since 2022 under the brand names Mounjaro and Zepbound, both manufactured by Eli Lilly, it is currently FDA-approved for type 2 diabetes and for weight management in adults with obesity.<\/p>\n\n<p>In contrast, <a href=\"\/th\/product\/buy-retatrutide-bangkok\/\">\u0e40\u0e23\u0e17\u0e41\u0e17\u0e23\u0e17\u0e23\u0e39\u0e44\u0e17\u0e14\u0e4c<\/a> is a triple agonist. While it activates the same two receptors as Tirzepatide, it also targets a third: the glucagon receptor. This additional mechanism is what separates it from every other compound in its class. Although also developed by Eli Lilly, Retatrutide remains investigational and has not yet received FDA approval. Currently in <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06662383\" target=\"_blank\" rel=\"noopener\">Phase 3 clinical trials<\/a>, a head-to-head comparison against Tirzepatide is expected to report results in December 2026.<\/p>\n\n<h2>How the mechanisms differ<\/h2>\n\n<p>At their core, both compounds slow gastric emptying, reduce appetite, and improve insulin sensitivity through GLP-1 and GIP receptor activation. As a result, there is significant overlap in their effects.<\/p>\n\n<p>However, the key difference is glucagon. Retatrutide\u2019s activation of the glucagon receptor adds a metabolic dimension that Tirzepatide does not have. Specifically, glucagon promotes the breakdown of stored fat for energy and increases resting energy expenditure. In practical terms, Tirzepatide primarily reduces how much energy goes in, whereas Retatrutide does that and also increases how much energy goes out.<\/p>\n\n<p>Consequently, this dual approach \u2014 less in, more out \u2014 is a key reason researchers have shown particular interest in Retatrutide\u2019s body composition effects beyond simple weight reduction.<\/p>\n\n<h2>What the clinical data shows<\/h2>\n\n<p>On the Tirzepatide side, the landmark SURMOUNT-1 trial showed an average body weight reduction of approximately 21% over 72 weeks at the highest dose. Furthermore, the more recent SURMOUNT-5 trial demonstrated 20.2% weight reduction at 72 weeks, significantly outperforming semaglutide\u2019s 13.7% in the same study.<\/p>\n\n<p>Meanwhile, Retatrutide\u2019s Phase 2 data reported approximately 24% average weight loss in just 48 weeks. Moreover, Phase 3 results showed participants on the 12mg dose losing an average of 28% of body weight over 80 weeks.<\/p>\n\n<p>To put these numbers in perspective, a <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12544991\/\" target=\"_blank\" rel=\"noopener\">2025 network meta-analysis<\/a> published in the Journal of the Endocrine Society compared the two compounds across 12 clinical trials. According to the analysis, Retatrutide showed greater absolute weight reduction (16.34 kg vs 11.82 kg) and greater percentage weight loss (23.77% vs 16.79%). Nevertheless, adverse events were more frequent with Retatrutide.<\/p>\n\n<h2>Side effect profiles<\/h2>\n\n<p>As with most GLP-1 receptor agonists, both compounds share common GI-related side effects: nausea, diarrhea, vomiting, and decreased appetite. Generally, these tend to be most pronounced during dose escalation and typically diminish over time.<\/p>\n\n<p>That said, the meta-analysis data indicates Retatrutide may carry a higher frequency of adverse events compared to Tirzepatide. This is largely consistent with what you would expect from a compound activating an additional receptor pathway \u2014 in other words, more biological activity means more potential for side effects alongside greater efficacy.<\/p>\n\n<h2>Research beyond weight<\/h2>\n\n<p>In addition to weight management, Tirzepatide is being studied for cardiovascular risk reduction, obstructive sleep apnea, and metabolic dysfunction-associated liver disease (MASLD). Because of its approved status, a broader base of real-world data is available across these applications.<\/p>\n\n<p>On the other hand, Retatrutide\u2019s early research suggests potential advantages in kidney function preservation in diabetic models and more pronounced effects on body fat composition specifically. Additionally, the glucagon receptor component may offer unique benefits in hepatic fat reduction and metabolic rate that Tirzepatide\u2019s dual mechanism does not address.<\/p>\n\n<h2>Quick comparison<\/h2>\n\n<table>\n<thead>\n<tr><th><\/th><th>\u0e40\u0e23\u0e17\u0e41\u0e17\u0e23\u0e17\u0e23\u0e39\u0e44\u0e17\u0e14\u0e4c<\/th><th>Tirzepatide<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td><strong>Receptors<\/strong><\/td><td>GLP-1 + GIP + Glucagon<\/td><td>GLP-1 + GIP<\/td><\/tr>\n<tr><td><strong>Type<\/strong><\/td><td>Triple agonist<\/td><td>Dual agonist<\/td><\/tr>\n<tr><td><strong>Status<\/strong><\/td><td>Investigational (Phase 3)<\/td><td>FDA-approved<\/td><\/tr>\n<tr><td><strong>Max weight loss<\/strong><\/td><td>~28% at 80 weeks<\/td><td>~21% at 72 weeks<\/td><\/tr>\n<tr><td><strong>Developer<\/strong><\/td><td>Eli Lilly<\/td><td>Eli Lilly<\/td><\/tr>\n<tr><td><strong>Unique edge<\/strong><\/td><td>Increased energy expenditure<\/td><td>Established safety data<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<h2>Which one for your research?<\/h2>\n\n<p>Overall, Tirzepatide has a larger body of published clinical data and an established safety profile from years of real-world use. Therefore, for research requiring a well-characterized compound with extensive literature, it remains the more documented option.<\/p>\n\n<p>In comparison, Retatrutide represents the next generation of incretin-based research. Its triple-agonist mechanism and the emerging data on superior weight reduction make it the compound to watch for researchers exploring the frontier of metabolic peptide science. Most importantly, the glucagon receptor component opens research avenues that dual agonists simply cannot access.<\/p>\n\n<p>As a result, many researchers now study both compounds in parallel to understand how the addition of glucagon receptor agonism changes outcomes across different metabolic parameters. For recovery and body composition research, compounds like <a href=\"\/th\/product\/buy-bpc-157-bangkok\/\">\u0e1a\u0e35\u0e1e\u0e35\u0e0b\u0e35-157<\/a>, <a href=\"\/th\/product\/buy-tb500-bangkok\/\">TB-500<\/a>, and <a href=\"\/th\/product\/buy-mots-c-bangkok\/\">MOTS-C<\/a> are commonly studied alongside metabolic peptides. For proper handling of all compounds, our <a href=\"\/th\/blog\/how-to-reconstitute-and-store-peptides\/\">reconstitution guide<\/a> covers everything you need.<\/p>\n\n<div class=\"blog-cta\">\n  <h2>Both available at Bangkok Peptide Center<\/h2>\n  <p>Same-day delivery in Bangkok. 99%+ purity. Free water and needles with every order.<\/p>\n  <a href=\"\/th\/product\/buy-retatrutide-bangkok\/\">Shop Retatrutide \u2192<\/a>\n  <a href=\"\/th\/product\/buy-tirzepatide-bangkok\/\" class=\"secondary\">Shop Tirzepatide \u2192<\/a>\n<\/div>\n\n<div class=\"source-list\">\n  <strong>Sources<\/strong>\n  <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06662383\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov \u2014 Retatrutide vs Tirzepatide Phase 3 (NCT06662383)<\/a><br>\n  <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12544991\/\" target=\"_blank\" rel=\"noopener\">Journal of the Endocrine Society \u2014 Comparative Efficacy Meta-Analysis (2025)<\/a><br>\n  <a href=\"https:\/\/www.drugs.com\/medical-answers\/how-retatrutide-compare-tirzepatide-3580916\/\" target=\"_blank\" rel=\"noopener\">Drugs.com \u2014 Retatrutide vs Tirzepatide Overview<\/a><br>\n  <a href=\"https:\/\/www.goodrx.com\/conditions\/weight-loss\/retatrutide-vs-tirzepatide\" target=\"_blank\" rel=\"noopener\">GoodRx \u2014 Retatrutide vs Tirzepatide Comparison<\/a>\n<\/div>\n\n<p class=\"blog-disclaimer\">For research and educational purposes only. All products supplied by Bangkok Peptide Center are not approved pharmaceutical products and are not intended for human use. Bangkok Peptide Center supplies research peptides strictly for laboratory research purposes. Always consult a qualified healthcare professional before considering any research compound.<\/p>\n\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Retatrutide and Tirzepatide are the two most researched GLP-1 receptor agonists in metabolic peptide science right now. Both target incretin [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[86],"tags":[203,202,199,198,200,204,201,205],"class_list":["post-421","post","type-post","status-publish","format-standard","hentry","category-research-guides","tag-dual-agonist","tag-glp-1-peptide","tag-metabolic-peptide-comparison","tag-retatrutide","tag-retatrutide-vs-tirzepatide","tag-tirzepatide","tag-triple-agonist","tag-weight-loss-peptide-bangkok"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Retatrutide vs Tirzepatide | Bangkok Peptide Center<\/title>\n<meta name=\"description\" content=\"Retatrutide vs Tirzepatide compared. Triple agonist vs dual agonist, clinical data, mechanisms, and side effects. Both available in Bangkok with same-day delivery. For research only.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bangkokpeptidecenter.com\/th\/retatrutide-vs-tirzepatide\/\" \/>\n<meta property=\"og:locale\" content=\"th_TH\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide vs Tirzepatide | Bangkok Peptide Center\" \/>\n<meta property=\"og:description\" content=\"Retatrutide vs Tirzepatide compared. Triple agonist vs dual agonist, clinical data, mechanisms, and side effects. Both available in Bangkok with same-day delivery. For research only.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bangkokpeptidecenter.com\/th\/retatrutide-vs-tirzepatide\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T23:25:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T23:25:43+00:00\" \/>\n<meta name=\"author\" content=\"Kagoshima\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kagoshima\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 \u0e19\u0e32\u0e17\u0e35\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/\"},\"author\":{\"name\":\"Kagoshima\",\"@id\":\"https:\/\/bangkokpeptidecenter.com\/#\/schema\/person\/a4edb27c8d1eef405563679379b0c19c\"},\"headline\":\"Retatrutide vs. Tirzepatide\",\"datePublished\":\"2026-06-05T23:25:42+00:00\",\"dateModified\":\"2026-06-05T23:25:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/\"},\"wordCount\":882,\"keywords\":[\"dual agonist\",\"GLP-1 peptide\",\"metabolic peptide comparison\",\"retatrutide\",\"retatrutide vs tirzepatide\",\"tirzepatide\",\"triple agonist\",\"weight loss peptide Bangkok\"],\"articleSection\":[\"Research Guides\"],\"inLanguage\":\"th\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/\",\"url\":\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/\",\"name\":\"Retatrutide vs Tirzepatide | Bangkok Peptide Center\",\"isPartOf\":{\"@id\":\"https:\/\/bangkokpeptidecenter.com\/#website\"},\"datePublished\":\"2026-06-05T23:25:42+00:00\",\"dateModified\":\"2026-06-05T23:25:43+00:00\",\"author\":{\"@id\":\"https:\/\/bangkokpeptidecenter.com\/#\/schema\/person\/a4edb27c8d1eef405563679379b0c19c\"},\"description\":\"Retatrutide vs Tirzepatide compared. Triple agonist vs dual agonist, clinical data, mechanisms, and side effects. Both available in Bangkok with same-day delivery. For research only.\",\"breadcrumb\":{\"@id\":\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/#breadcrumb\"},\"inLanguage\":\"th\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bangkokpeptidecenter.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide vs. Tirzepatide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bangkokpeptidecenter.com\/#website\",\"url\":\"https:\/\/bangkokpeptidecenter.com\/\",\"name\":\"\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bangkokpeptidecenter.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"th\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bangkokpeptidecenter.com\/#\/schema\/person\/a4edb27c8d1eef405563679379b0c19c\",\"name\":\"Kagoshima\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"th\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/46b4957e09a6bb91368a3b17256940b737b13e3ff0e7929a92a1c32dc0772358?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/46b4957e09a6bb91368a3b17256940b737b13e3ff0e7929a92a1c32dc0772358?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/46b4957e09a6bb91368a3b17256940b737b13e3ff0e7929a92a1c32dc0772358?s=96&d=mm&r=g\",\"caption\":\"Kagoshima\"},\"sameAs\":[\"http:\/\/bangkokpeptidecenter.com\"],\"url\":\"https:\/\/bangkokpeptidecenter.com\/th\/author\/purepassagesgmail-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Retatrutide vs Tirzepatide | Bangkok Peptide Center","description":"Retatrutide vs Tirzepatide compared. Triple agonist vs dual agonist, clinical data, mechanisms, and side effects. Both available in Bangkok with same-day delivery. For research only.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bangkokpeptidecenter.com\/th\/retatrutide-vs-tirzepatide\/","og_locale":"th_TH","og_type":"article","og_title":"Retatrutide vs Tirzepatide | Bangkok Peptide Center","og_description":"Retatrutide vs Tirzepatide compared. Triple agonist vs dual agonist, clinical data, mechanisms, and side effects. Both available in Bangkok with same-day delivery. For research only.","og_url":"https:\/\/bangkokpeptidecenter.com\/th\/retatrutide-vs-tirzepatide\/","article_published_time":"2026-06-05T23:25:42+00:00","article_modified_time":"2026-06-05T23:25:43+00:00","author":"Kagoshima","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Kagoshima","Est. reading time":"4 \u0e19\u0e32\u0e17\u0e35"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/#article","isPartOf":{"@id":"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/"},"author":{"name":"Kagoshima","@id":"https:\/\/bangkokpeptidecenter.com\/#\/schema\/person\/a4edb27c8d1eef405563679379b0c19c"},"headline":"Retatrutide vs. Tirzepatide","datePublished":"2026-06-05T23:25:42+00:00","dateModified":"2026-06-05T23:25:43+00:00","mainEntityOfPage":{"@id":"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/"},"wordCount":882,"keywords":["dual agonist","GLP-1 peptide","metabolic peptide comparison","retatrutide","retatrutide vs tirzepatide","tirzepatide","triple agonist","weight loss peptide Bangkok"],"articleSection":["Research Guides"],"inLanguage":"th"},{"@type":"WebPage","@id":"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/","url":"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/","name":"Retatrutide vs Tirzepatide | Bangkok Peptide Center","isPartOf":{"@id":"https:\/\/bangkokpeptidecenter.com\/#website"},"datePublished":"2026-06-05T23:25:42+00:00","dateModified":"2026-06-05T23:25:43+00:00","author":{"@id":"https:\/\/bangkokpeptidecenter.com\/#\/schema\/person\/a4edb27c8d1eef405563679379b0c19c"},"description":"Retatrutide vs Tirzepatide compared. Triple agonist vs dual agonist, clinical data, mechanisms, and side effects. Both available in Bangkok with same-day delivery. For research only.","breadcrumb":{"@id":"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/#breadcrumb"},"inLanguage":"th","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bangkokpeptidecenter.com\/retatrutide-vs-tirzepatide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bangkokpeptidecenter.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide vs. Tirzepatide"}]},{"@type":"WebSite","@id":"https:\/\/bangkokpeptidecenter.com\/#website","url":"https:\/\/bangkokpeptidecenter.com\/","name":"","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bangkokpeptidecenter.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"th"},{"@type":"Person","@id":"https:\/\/bangkokpeptidecenter.com\/#\/schema\/person\/a4edb27c8d1eef405563679379b0c19c","name":"Kagoshima","image":{"@type":"ImageObject","inLanguage":"th","@id":"https:\/\/secure.gravatar.com\/avatar\/46b4957e09a6bb91368a3b17256940b737b13e3ff0e7929a92a1c32dc0772358?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/46b4957e09a6bb91368a3b17256940b737b13e3ff0e7929a92a1c32dc0772358?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/46b4957e09a6bb91368a3b17256940b737b13e3ff0e7929a92a1c32dc0772358?s=96&d=mm&r=g","caption":"Kagoshima"},"sameAs":["http:\/\/bangkokpeptidecenter.com"],"url":"https:\/\/bangkokpeptidecenter.com\/th\/author\/purepassagesgmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/posts\/421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/comments?post=421"}],"version-history":[{"count":1,"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/posts\/421\/revisions"}],"predecessor-version":[{"id":422,"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/posts\/421\/revisions\/422"}],"wp:attachment":[{"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/media?parent=421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/categories?post=421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bangkokpeptidecenter.com\/th\/wp-json\/wp\/v2\/tags?post=421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}